Privo Technologies   Report issue

For profit Phase 2
Founded: Peabody MA United States (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2018
NCT03502148
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

CEO, Privo Technologies | Privo Technologies

Active Ingredients

Drugs in Phase 2 Trials (1)

cisplatin (platinol) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1